Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Assets (2019 - 2025)

Burning Rock Biotech has reported Assets over the past 7 years, most recently at $115.7 million for Q4 2025.

  • For Q4 2025, Assets fell 6.15% year-over-year to $115.7 million; the TTM value through Dec 2025 reached $115.7 million, down 6.15%, while the annual FY2025 figure was $117.3 million, 3.28% down from the prior year.
  • Assets for Q4 2025 was $115.7 million at Burning Rock Biotech, up from $114.1 million in the prior quarter.
  • Over five years, Assets peaked at $409.4 million in Q1 2021 and troughed at $114.1 million in Q3 2025.
  • A 5-year average of $215.5 million and a median of $171.7 million in 2023 define the central range for Assets.
  • Biggest five-year swings in Assets: dropped 5.53% in 2021 and later plummeted 37.93% in 2023.
  • Year by year, Assets stood at $356.4 million in 2021, then crashed by 37.37% to $223.2 million in 2022, then tumbled by 35.29% to $144.4 million in 2023, then fell by 14.67% to $123.2 million in 2024, then decreased by 6.15% to $115.7 million in 2025.
  • Business Quant data shows Assets for BNR at $115.7 million in Q4 2025, $114.1 million in Q3 2025, and $115.2 million in Q2 2025.